Verseon Presents Second Anticoagulation Candidate for Clinical Trials at AHA 2017

09:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Verseon presented preclinical data on its second anticoagulant candidate, VE-2851, at this week’s American Heart Association conference (Scientific Sessions 2017). VE-2851 shows excellent efficacy paired with low bleedi...

Other Sources for this Article

Verseon Corporation:
Tina Schlafly
+1 (510) 225 9000
Trade and pharma media:
Vane Percy & Roberts
Simon Vane Percy
+44 (0) 1737 821 890


More From BioPortfolio on "Verseon Presents Second Anticoagulation Candidate for Clinical Trials at AHA 2017"

Quick Search


Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...